Clinical trial
A Phase 2, Randomized, Placebo-controlled, Double-Blind Multicenter Study to Assess the Safety, Tolerability, and Pharmacodynamics (PD) in Adult Participants With Mild-to Moderate Alzheimer's Disease (AD) Administered SPG302
NCT06427668 is registered in ClinicalTrials.gov with Spinogenix as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Placebo-controlled, Double-Blind Multicenter Study to Assess the Safety, Tolerability, and Pharmacodynamics (PD) in Adult Participants With Mild-to Moderate Alzheimer's Disease (AD) Administered SPG302
- Lead sponsor
- Spinogenix
- Phase
- Phase 2
- Overall status
- Active, not recruiting
- Start date
- July 29, 2024
- Completion date
- June 30, 2026
- Enrollment
- 24 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.